Furthermore, as the three uORFs found in JAK2 constitutively repressed the translation of JAK2, and with clinical sequence research reporting an uORF mutation of JAK2 in a patient with chronic lymphocytic leukemia49, it appears the mutation of uORFs in JAK2 is a high-risk factor, and more in-depth sequencing of the 5ʹ UTR is needed in patients with myeloproliferative diseases. The gene discussed is JAK2; the disease is myeloproliferative disorder.